Retention of Secukinumab Treatment in Adults with Plaque Psoriasis and Metabolic Liver Disease Using Electronic Medical Records in Spain

What this Trial Is About

Researchers are studying the retention rate of secukinumab treatment in adults with plaque psoriasis, with or without psoriatic arthritis, who also have metabolic dysfunction-associated steatotic liver disease MASLD. This observational study uses electronic medical record data from multiple hospitals in Spain to better understand how patients maintain this therapy in routine clinical practice and how liver-related biomarkers change over time. The study focuses on adult patients who have started secukinumab between January 2021 and December 2023 as their first, second, or third biologic therapy for psoriasis or psoriatic arthritis. Patients must have confirmed plaque psoriasis with or without PsA, MASLD diagnosis, and at least one cardiometabolic risk factor. Researchers will observe the patients treatment retention and monitor liver and psoriasis biomarkers, including fibrosis scores and liver enzyme levels, over up to five years. Participants will have their medical records reviewed for treatment discontinuation events and biomarker changes at baseline and multiple follow-up points up to 60 months. Outcomes include psoriasis severity scores and liver fibrosis indices measured regularly. This long-term observation aims to assess the relationship between psoriasis treatment and liver health changes, with data collected from routine clinical care without additional interventions or procedures.

A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD